

Table S3. Antibiotic susceptibility of 26 carbapenemase-producing *Escherichia coli* isolates as determined by the microdilution method and antibiotic gradient strips (antibiotics with *) according to EUCAST clinical breakpoints.

| Antibiotics | S (%) | R (%) | MIC ₅₀ * | MIC ₉₀ * | Range* |
|-------------------------------|-------|-------|---------------------|---------------------|-------------|
| Meropenem/Vaborbactam* | 100 | 0 | 0.25 | 2 | 0.03 - 4 |
| Plazomicin* | 100 | 0 | 1 | 2 | 0.06 - 2 |
| Cefiderocol* | 96.2 | 3.8 | 0.03 | 0.25 | ≤0.015 - 4 |
| Colistin | 92.3 | 7.7 | 1 | 1 | 0.5 - 8 |
| Meropenem | 88.5 | 0 | 1 | 3 | 0.25 - 8 |
| Imipenem/Relebactam* | 84.6 | 15.4 | 1 | 4 | 0.25 - 8 |
| Tigecycline | 84.6 | 15.4 | 0.5 | 1 | ≤0.25 - 1 |
| Amikacin | 84.6 | 15.4 | ≤4 | 16 | ≤4 - 16 |
| Ceftazidime/Avibactam | 76.9 | 23.1 | ≤0.5 | >16 | ≤0.5 - >16 |
| Imipenem | 69.2 | 7.7 | 2 | 4 | ≤0.5 - 16 |
| Gentamicin | 65.4 | 34.6 | 1 | >8 | ≤0.5 - >8 |
| Tobramycin | 57.7 | 42.3 | ≤1 | >8 | ≤1 - >8 |
| Cefepime* | 50 | 46.2 | 2.5 | 32 | 0.12 - >256 |
| Aztreonam | 50 | 38.5 | 1.5 | >32 | ≤0.5 - >32 |
| Trimethoprim/Sulfamethoxazole | 46.2 | 53.8 | >8 | >8 | ≤1 - >8 |
| Ceftazidime | 42.3 | 53.8 | 16 | >16 | ≤0.5 - >16 |
| Ceftolozane/Tazobactam | 42.3 | 57.7 | 12 | >32 | ≤0.5 - >32 |
| Cefotaxime | 23.1 | 61.5 | >8 | >8 | ≤0.5 - >8 |
| Ciprofloxacin | 19.2 | 76.9 | >2 | >2 | ≤0.06 - >2 |
| Ertapenem | 15.4 | 84.6 | 2 | >2 | 0.5 - >2 |
| Piperacillin/Tazobactam | 0 | 100 | >32 | >32 | >32 - >32 |

S: susceptible. R: resistant. MIC: minimum inhibitory concentrations.

* Expressed in mg/L.